Latest News-Harbour Biomed Mediaroom_Page

Nona Biosciences Appoints Steve Arkinstall, D. Phil., as Chief Scientific Advisor

CAMBRIDGE, Mass., June 6, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM H...

2023-06-07 09:00 3218

Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020

* HBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinica...

2023-06-05 09:01 2801

Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023

* Porustobart in combination of toripalimab showed promising anti-tumor activity * Porustobart ...

2023-05-29 09:42 2890

Nona Biosciences Enters into Antibody Discovery Agreement with OPKO Health's ModeX Therapeutics

CAMBRIDGE, Mass., May 23, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM H...

2023-05-23 13:00 2044

Nona Biosciences Announces Strategic Collaboration Agreement with PharmaEssentia Innovation Research Center

CAMBRIDGE, Mass., May 11, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM H...

2023-05-12 09:32 2906

Nona Biosciences and Washington University Join Forces to Tackle Emerging RNA Viruses

CAMBRIDGE, Mass., April 18, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM...

2023-04-19 08:45 2718

Nona Biosciences Enters into Collaboration Agreement with ExeVir Bio

CAMBRIDGE, Mass., April 5, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM ...

2023-04-06 10:20 3165

Harbour BioMed Reports Full Year 2022 Financial Results

CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 3, 2023 /PRNewswire/ -- Harbour B...

2023-04-03 15:10 4296

Harbour BioMed Announces Positive Topline Results from Phase III Trial of Batoclimab for Treatment of Generalized Myasthenia Gravis

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 6, 2023 /PRNewswire/ -- Harbour B...

2023-03-06 14:27 3024

Nona Biosciences Enters into HCAb Based Antibody Discovery Collaboration Agreement with Mythic Therapeutics

CAMBRIDGE, Mass., Feb. 10, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM ...

2023-02-10 13:00 2707

HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders

CAMBRIDGE, Mass., Jan. 26, 2023 /PRNewswire/ -- HBM Alpha Therapeutics (HBMAT), Inc., an innovative...

2023-01-26 09:22 3689

Nona Biosciences Enters into HCAb Based Drug Discovery Collaboration Agreement with Dragonfly Therapeutics

CAMBRIDGE, Mass., Nov. 21, 2022 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM ...

2022-11-21 17:31 3463

Nona Biosciences Announces Attendance at PEGS Europe 2022

CAMBRIDGE, Mass., Nov. 15, 2022 /PRNewswire/ -- Nona Biosciences (a wholly-owned subsidiary of HBM ...

2022-11-15 15:57 2839

Nona Biosciences Announces Attendance at PEGS Europe 2022

HARBOUR BIOMED LAUNCHES NONA BIOSCIENCES' "IDEAS TO IND" PRECLINICAL SOLUTIONS BUSINESS TO ACCELERATE GLOBAL BIOTHERAPEUTIC INNOVATION

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 14, 2022 /PRNewswire/ -- Harbor Bi...

2022-11-15 12:19 2490

Latest News